Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 851311 / ISIN: CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

17.03.25		Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference (Roche Holding AG)
17.03.25		Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference (GlobeNewswire)
12.03.25		Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight an (GlobeNewswire)
07.03.25		Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston (GlobeNewswire)
07.03.25		Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston (Roche Holding AG)
05.03.25		FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis (Roche Holding AG)
05.03.25		FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis (GlobeNewswire)
02.03.25		Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies (Roche Holding AG)
02.03.25		Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies (GlobeNewswire)
28.02.25		CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
28.02.25		CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
20.02.25		Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology (GlobeNewswire)
20.02.25		Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology (Roche Holding AG)
12.02.25		FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) (GlobeNewswire)
12.02.25		FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) (Roche Holding AG)
07.02.25		New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis (GlobeNewswire)
07.02.25		New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis (Roche Holding AG)
04.02.25		FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness (GlobeNewswire)
04.02.25		FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness (Roche Holding AG)
31.01.25		Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU (Roche Holding AG)
31.01.25		Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU (GlobeNewswire)
30.01.25		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth (Roche Holding AG)
30.01.25		[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum (GlobeNewswire)
30.01.25		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth (GlobeNewswire)
29.01.25		Change to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
29.01.25		Change to the Roche Enlarged Corporate Executive Committee (GlobeNewswire)
28.01.25		Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer (Roche Holding AG)
28.01.25		Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer (GlobeNewswire)
27.01.25		Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) (Roche Holding AG)
27.01.25		Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) (GlobeNewswire)
22.01.25		Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care (Roche Holding AG)
22.01.25		Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care (GlobeNewswire)
08.01.25		Roche purchases shares in tender offer for Poseida Therapeutics, Inc. (Roche Holding AG)
08.01.25		Roche purchases shares in tender offer for Poseida Therapeutics, Inc. (GlobeNewswire)
19.12.24		Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (Roche Holding AG)
19.12.24		Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (GlobeNewswire)
18.12.24		Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (GlobeNewswire)
18.12.24		Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (Roche Holding AG)
13.12.24		Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness (GlobeNewswire)
13.12.24		Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (Roche Holding AG)
13.12.24		Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (GlobeNewswire)
10.12.24		New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (Roche Holding AG)
10.12.24		New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (GlobeNewswire)
09.12.24		Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (GlobeNewswire)
09.12.24		Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (Roche Holding AG)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (Roche Holding AG)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (GlobeNewswire)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
26.11.24		Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (GlobeNewswire)

1 | Weiter

Newssuche

Roche Peer Group Nachrichten

20:19		Bayer-Aktie sackt ab: Glyphosat-Klage - Niederlage für Bayer vor US-Gericht
20:05		Gute Stimmung in New York: So performt der Dow Jones am Montagnachmittag
20:05		NASDAQ 100-Handel aktuell: NASDAQ 100 mit Zuschlägen
18:03		Freundlicher Handel: NASDAQ 100 freundlich
18:03		Dow Jones-Handel aktuell: Anleger lassen Dow Jones steigen
17:59		Schwache Performance in Europa: Euro STOXX 50 schwächelt schlussendlich
17:59		Anleger in Zürich halten sich zurück: SPI präsentiert sich zum Ende des Montagshandels schwächer
17:59		Börse Europa in Rot: STOXX 50 präsentiert sich schlussendlich leichter

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	24.03.2025 22:02
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie

WKN: 851311 / ISIN: CH0012032113

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten